and evaluated. In addition, all patients received a detailed headache diary during the first visit that assessed daily and symptomatic medication intake as well as headache severity and duration. Adherence, as expressed by complying with the prescribed medication in ≥80% of the days, which is a common operational definition of adequate medication adherence across a number of health conditions [11] [12] [13] , was evaluated by using a headache diary and a face-to-face interview during the follow-up consultation. It was compared between the patients taking one or more drugs as well. The headaches were classified according to International Classification of Headache Disorders (ICHD-II) 14 and the ICHD-II appendix 15 to classify chronic migraine and MOH. The Ethics Committee of Universidade Federal Fluminense approved the study. Statistics differences were analyzed using the Z-Test for proportions. In all analyses, p values less than 0.05 were considered significant.
RESULTS
Among the 500 patients, 71.8% were women. Ages ranged from 4 to 88 years (mean 38.7±14.7). The peak prevalence was between 31 and 40 years either for women or men. The average headache duration was 20.2 years (0.1 to 80 years, standard deviation (SD) 13.4). The diagnoses were 48.5% episodic migraine without aura, 6.2% episodic migraine with aura, 7.3% chronic migraine and 38% MOH and migraine.
The prophylactic treatment was prescribed to 470 (94%) patients in the first visit. Thirty (6%) of them did not receive preventive medication, 57 (11.4%) received one drug, 111 (22.2%) two drugs, 207 (41.4%) three drugs and 95 (19%) received an association of four preventive medications. The most prescribed combination of prophylactic medications, was a tricyclic antidepressant, a beta-blocker and flunarizine for 81 (16.2%), followed by combination of a tricyclic antidepressant, a muscle relaxant and flunarizine for 74 (14.8%). Sixty-two (12.4%) patients received a tricyclic antidepressant, a beta-blocker, a muscle relaxant and flunarizine. The overall adherence was 79.6% (p<0.001). Adherence to medications prescribed on monotherapy or in combination is showed in Figure. Comparison of adherence to different treatment regimens is depicted in Table. 
DISCUSSION
The literature on adherence in headache treatment is scarce. The evidence available is consistent with the broader medical literature in chronic conditions indicating poor adherence to recommendations for acute and prophylactic medication use and appointment-keeping among headache patients 13 . Between 25 and 50% of patients have been shown noncompliant with prophylactic headache medications 4, 5 . A large survey yielding data from 1,160 severe headache patients demonstrated that the most common reasons for not filling a prescription were high cost (33%) and safety concerns (30%) 14 . Reports from Literature have demonstrated that compliance decreases with more frequent or complex dosing regimens 4, 6 , however we did not find studies that correlate number of medications prescribed with adherence in the preventive treatment of headaches. By analyzing the table, one can observe that there is no statistical difference between adherence to treatments in monotherapy or in combination of medications, suggesting a rate even higher of adherence among those patients who received 3 or 4 drugs, when compared with those who received 2 drugs. It was different from our initial belief that prescribing more than one drug during the first visit could impair adherence, since tolerability and safety concerns would arise from wrong patient assumptions.
The overall adherence in our study was greater than that demonstrated in the literature 4, 5 . Edmeads et al 15 demonstrated that, after the initial consultation, 40% of patients did not return for the follow-up, and 24% dropped out later. Likewise, Spierings et al 16 reported that 40.5% of patients did not comply with their recommendation for a follow-up treatment appointment after their initial consultation. 
